{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T17:14:30Z","timestamp":1783703670277,"version":"3.55.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiol Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40119-026-00452-w","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T14:46:08Z","timestamp":1779893168000},"page":"231-253","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient Perspectives on Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Attributes"],"prefix":"10.1007","volume":"15","author":[{"given":"Nisith","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Coulter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Haddad-Angulo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Baig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haechung","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjana Mahalakshmi","family":"Chandrasekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Vass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayne","family":"Galinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Marie","family":"Carr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine","family":"McIntosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Hauber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"issue":"22","key":"452_CR1","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","volume":"73","author":"FL Ruberg","year":"2019","unstructured":"Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73(22):2872\u201391. https:\/\/doi.org\/10.1016\/j.jacc.2019.04.003.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"452_CR2","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1001\/jama.2024.0442","volume":"331","author":"FL Ruberg","year":"2024","unstructured":"Ruberg FL, Maurer MS. Cardiac amyloidosis due to transthyretin protein: a review. JAMA. 2024;331(9):778\u201391. https:\/\/doi.org\/10.1001\/jama.2024.0442.","journal-title":"JAMA"},{"key":"452_CR3","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.pcad.2024.01.013","volume":"82","author":"J Vaishnav","year":"2024","unstructured":"Vaishnav J, Brown E, Sharma K. Advances in the diagnosis and treatment of transthyretin amyloid cardiomyopathy. Prog Cardiovasc Dis. 2024;82:113\u201324. https:\/\/doi.org\/10.1016\/j.pcad.2024.01.013. (Epub 2024 Jan 20)","journal-title":"Prog Cardiovasc Dis"},{"issue":"4","key":"452_CR4","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/ejhf.2776","volume":"25","author":"A Porcari","year":"2023","unstructured":"Porcari A, Razvi Y, Masi A, et al. Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy. Eur J Heart Fail. 2023;25(4):515\u201324. https:\/\/doi.org\/10.1002\/ejhf.2776.","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"452_CR5","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jacc.2020.11.006","volume":"77","author":"C Nitsche","year":"2021","unstructured":"Nitsche C, Scully PR, Patel KP, et al. Prevalence and outcomes of concomitant aortic stenosis and cardiac amyloidosis. J Am Coll Cardiol. 2021;77(2):128\u201339. https:\/\/doi.org\/10.1016\/j.jacc.2020.11.006.","journal-title":"J Am Coll Cardiol"},{"key":"452_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1238843","volume":"10","author":"L Ponti","year":"2023","unstructured":"Ponti L, Hsu K, Damy T, et al. Burden of untreated transthyretin amyloid cardiomyopathy on patients and their caregivers by disease severity: results from a multicenter, non-interventional, real-world study. Front Cardiovasc Med. 2023;10:1238843. https:\/\/doi.org\/10.3389\/fcvm.2023.1238843.","journal-title":"Front Cardiovasc Med"},{"key":"452_CR7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ejim.2024.01.001","volume":"123","author":"A Porcari","year":"2024","unstructured":"Porcari A, Sinagra G, Gillmore JD, Fontana M, Hawkins PN. Breakthrough advances enhancing care in ATTR amyloid cardiomyopathy. Eur J Intern Med. 2024;123:29\u201336. https:\/\/doi.org\/10.1016\/j.ejim.2024.01.001.","journal-title":"Eur J Intern Med"},{"issue":"1","key":"452_CR8","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.cpcardiol.2017.04.003","volume":"43","author":"S Bhogal","year":"2018","unstructured":"Bhogal S, Ladia V, Sitwala P, et al. Cardiac amyloidosis: an updated review with emphasis on diagnosis and future directions. Curr Probl Cardiol. 2018;43(1):10\u201334. https:\/\/doi.org\/10.1016\/j.cpcardiol.2017.04.003.","journal-title":"Curr Probl Cardiol"},{"key":"452_CR9","unstructured":"Alnylam Pharmaceuticals. Patisiran prescribing information. January 2023. https:\/\/www.alnylam.com\/sites\/default\/files\/pdfs\/ONPATTRO-Prescribing-Information.pdf. Accessed 16 February 2025."},{"key":"452_CR10","unstructured":"Alnylam Pharmaceuticals. Vutrisiran prescribing information. February 2023. https:\/\/www.alnylam.com\/sites\/default\/files\/pdfs\/ONPATTRO-Prescribing-Information.pdf. Accessed 16 February 2025."},{"key":"452_CR11","unstructured":"AstraZeneca Pharmaceuticals. Eplontersen prescribing information. September 2024. https:\/\/www.wainuahcp.com\/. Accessed 16 February 2025."},{"key":"452_CR12","unstructured":"Pfizer Inc. Tafamidis prescribing information. October 2023. https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=11685. Accessed 16 February 2025."},{"key":"452_CR13","unstructured":"BridgeBio. Acoramidis prescribing information. November 2024. https:\/\/attruby.com\/attruby-prescribing-information.pdf. Accessed 16 February 2025."},{"issue":"25","key":"452_CR14","doi-asserted-by":"publisher","first-page":"07719","DOI":"10.1016\/j.jacc.2025.09.004","volume":"S0735\u20131097","author":"MM Kittleson","year":"2025","unstructured":"Kittleson MM, Ambardekar AV, Cheng RK, Griffin JM, Maurer MS, Nativi-Nicolau J, et al. Transthyretin cardiac amyloidosis evaluation and management: 2025 ACC Concise Clinical Guidance. J Am Coll Cardiol. 2025;S0735\u20131097(25):07719\u201328. https:\/\/doi.org\/10.1016\/j.jacc.2025.09.004.","journal-title":"J Am Coll Cardiol"},{"key":"452_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-025-00736-8","author":"DA Marshall","year":"2025","unstructured":"Marshall DA, MacDonald KV, Suryaprakash N, Mirza RM, Sewitch MJ, Nguyen GC. Incorporating best\u2013worst scaling (BWS) questions into focus groups to improve understanding of patient preferences and refine BWS attributes. Patient. 2025. https:\/\/doi.org\/10.1007\/s40271-025-00736-8.","journal-title":"Patient"},{"key":"452_CR16","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1007\/s40273-016-0429-5","volume":"34","author":"KL Cheung","year":"2016","unstructured":"Cheung KL, Wijnen BF, Hollin IL, et al. Using best\u2013worst scaling to investigate preferences in health care. Pharmacoeconomics. 2016;34:1195\u2013209.","journal-title":"Pharmacoeconomics"},{"key":"452_CR17","unstructured":"Qualitrics. MaxDiff analysis security statement. https:\/\/www.qualtrics.com\/support\/conjoint-project\/getting-started-conjoints\/getting-started-maxdiff\/maxdiff-analysis-white-paper\/. Accessed 13 February 2025."},{"issue":"5","key":"452_CR18","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s40271-014-0099-3","volume":"8","author":"TL Laba","year":"2015","unstructured":"Laba TL, Essue B, Kimman M, Jan S. Understanding patient preferences in medication nonadherence: a review of stated preference data. Patient. 2015;8(5):385\u201395. https:\/\/doi.org\/10.1007\/s40271-014-0099-3.","journal-title":"Patient"},{"key":"452_CR19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.33393\/dti.2021.2342","volume":"15","author":"S Losi","year":"2021","unstructured":"Losi S, Berra CCF, Fornengo R, Pitocco D, Biricolti G, Federici MO. The role of patient preferences in adherence to treatment in chronic disease: a narrative review. Drug Target Insights. 2021;15:13\u201320. https:\/\/doi.org\/10.33393\/dti.2021.2342.","journal-title":"Drug Target Insights"},{"issue":"5","key":"452_CR20","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1002\/ehf2.14736","volume":"11","author":"T Kato","year":"2024","unstructured":"Kato T, Ines M, Minamisawa M, Benjumea D, Keohane D, Alvir J, et al. Tafamidis medication adherence and persistence in patients with transthyretin amyloid cardiomyopathy in Japan. ESC Heart Fail. 2024;11(5):2881\u20138.","journal-title":"ESC Heart Fail"},{"issue":"2","key":"452_CR21","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s40119-024-00365-6","volume":"13","author":"S Attal","year":"2024","unstructured":"Attal S, Kemner J, Alvir J, Barth S, Schuessler S. Tafamidis 61 mg patient characteristics and persistency? A retrospective analysis of German statutory health insurance data (IQVIA\u2122 LRx). Cardiol Ther. 2024;13(2):369\u201378.","journal-title":"Cardiol Ther"},{"key":"452_CR22","doi-asserted-by":"crossref","unstructured":"Chandrasekar S, Wright J, Garratt-Wheeldon J, Chung J, In\u00eas MS, Baker CL, et al. (2025) Patterns of treatment, adherence, and administration preferences for people with transthyretin amyloid cardiomyopathy: a real-world survey in Europe, the United States, and Japan. Poster presented at ISPOR Europe, Glasgow, UK.","DOI":"10.1016\/j.jval.2025.09.1745"},{"issue":"14","key":"452_CR23","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.2147\/PPA.S276328","volume":"10","author":"KE Trinkley","year":"2020","unstructured":"Trinkley KE, Kahn MG, Allen LA, Haugen H, Kroehl ME, Lin CT, et al. Patient treatment preferences for heart failure medications: a mixed methods study. Patient Prefer Adherence. 2020;10(14):2225\u201330.","journal-title":"Patient Prefer Adherence"},{"issue":"2","key":"452_CR24","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.cjco.2022.11.013","volume":"5","author":"BJ MacDonald","year":"2022","unstructured":"MacDonald BJ, Barry AR, Turgeon RD. Decisional needs and patient treatment preferences for heart failure medications: a scoping review. CJC Open. 2022;5(2):136\u201347. https:\/\/doi.org\/10.1016\/j.cjco.2022.11.013.","journal-title":"CJC Open"}],"container-title":["Cardiology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-026-00452-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40119-026-00452-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-026-00452-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T16:33:47Z","timestamp":1783701227000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40119-026-00452-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["452"],"URL":"https:\/\/doi.org\/10.1007\/s40119-026-00452-w","relation":{},"ISSN":["2193-8261","2193-6544"],"issn-type":[{"value":"2193-8261","type":"print"},{"value":"2193-6544","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]},"assertion":[{"value":"11 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ordering of figures 2, 3 and 4 updated.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Nisith Kumar, Joshua Coulter, Alexandra Haddad-Angulo, Louis Baig, Haechung Chung, Sanjana Mahalakshmi Chandrasekasr, and Brett Hauber are employees and own stock in Pfizer Inc., the funder of this study. Caroline Vass is an employee of RTI Health Solutions, an independent nonprofit research organization, which was retained by Pfizer to contribute to the research thatis the subject of this manuscript. Jayne Galinsky was an employee of RTI Health Solutions at the time of the study and is currently affiliated with Glasgow Caledonian University. Katharine McIntosh is an employee of Cardiomyopathy UK, which has received research funding from Pfizer Inc. Anne-Marie Carr has nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Salus IRB reviewed the study materials for the confirmatory survey and provided an exemption from full review on June 2, 2025 (study ID 23528).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}